{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T03:17:50Z","timestamp":1648523870950},"reference-count":97,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1016\/j.ijcard.2006.05.071","type":"journal-article","created":{"date-parts":[[2006,8,10]],"date-time":"2006-08-10T11:36:00Z","timestamp":1155209760000},"page":"296-305","source":"Crossref","is-referenced-by-count":8,"title":["Congestive heart failure-related anemia and a role for erythropoietin"],"prefix":"10.1016","volume":"117","author":[{"given":"Kamran","family":"Akram","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian L.","family":"Pearlman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2006.05.071_bib1","series-title":"Heart Disease","first-page":"635","author":"Braunwald","year":"2001"},{"key":"10.1016\/j.ijcard.2006.05.071_bib2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"SOLVD Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2006.05.071_bib3","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2006.05.071_bib4","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2006.05.071_bib5","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2006.05.071_bib6","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0735-1097(03)00245-6","article-title":"Heart failure therapy at a crossroad: are there limits to the neurohormonal model?","volume":"41","author":"Mehra","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2006.05.071_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.carrev.2005.06.002","article-title":"The deadly triangle of anemia, renal insufficiency, and cardiovascular disease: implications for prognosis and treatment","volume":"6","author":"McCullough","year":"2005","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.ijcard.2006.05.071_bib8","first-page":"749","article-title":"The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron?","volume":"17","author":"Silverberg","year":"2004","journal-title":"J Nephrol"},{"key":"10.1016\/j.ijcard.2006.05.071_bib9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/01.CIR.0000134279.79571.73","article-title":"Anemia and its relationship to clinical outcome in heart failure","volume":"110","author":"Anand","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2006.05.071_bib10","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1161\/01.CIR.0000162477.70955.5F","article-title":"Association of hemoglobin levels with clinical outcomes in acute coronary syndromes","volume":"111","author":"Sabatine","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2006.05.071_bib11","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/S0735-1097(02)01854-5","article-title":"Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure","volume":"39","author":"Horwich","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2006.05.071_bib12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1161\/01.CIR.0000052622.51963.FC","article-title":"Anemia is common in heart failure and is associated with poor outcomes","volume":"107","author":"Ezekowitz","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2006.05.071_bib13","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cardfail.2004.03.003","article-title":"Impact of congestive heart failure, chronic kidney disease, and anemia on survival in the Medicare population","volume":"10","author":"Herzog","year":"2004","journal-title":"J Card Fail"},{"key":"10.1016\/j.ijcard.2006.05.071_bib14","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0002-9149(00)01393-X","article-title":"Importance of heart failure with preserved systolic function in patients > or =65\u00a0years of age. Cardiovascular Health Study","volume":"87","author":"Kitzman","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2006.05.071_bib15","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1161\/CIRCULATIONAHA.105.582577","article-title":"Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program","volume":"113","author":"O'Meara","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2006.05.071_bib16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ahj.2005.03.056","article-title":"Anemia in patients with heart failure and preserved systolic function","volume":"151","author":"Felker","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijcard.2006.05.071_bib17","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1053\/ajkd.2001.21305","article-title":"Use of erythropoietin before the initiation of dialysis and its impact on mortality","volume":"37","author":"Fink","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ijcard.2006.05.071_bib18","doi-asserted-by":"crossref","first-page":"S1061","DOI":"10.1016\/S0735-1097(03)81778-3","article-title":"Anemia in ambulatory patients with chronic heart failure: a single-center clinical experience derived from electronic medical records","volume":"41","author":"Tang","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2006.05.071_bib19","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S1388-9842(02)00115-0","article-title":"The importance of anemia and its correction in the management of severe congestive heart failure","volume":"4","author":"Silverberg","year":"2002","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ijcard.2006.05.071_bib20","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.amjcard.2005.05.030","article-title":"Relation of lower Hct to progression from asymptomatic left ventricular dysfunction to symptomatic heart failure","volume":"96","author":"Das","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2006.05.071_bib21","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0735-1097(01)01470-X","article-title":"Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction","volume":"38","author":"Al-Ahmad","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2006.05.071_bib22","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1053\/ajkd.2001.29275","article-title":"Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter","volume":"38","author":"Levin","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ijcard.2006.05.071_bib23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2369-7-3","article-title":"Anemia and chronic kidney disease are associated with poor outcomes in heart failure patients","volume":"7","author":"Luthi","year":"2006","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ijcard.2006.05.071_bib24","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/ki.1995.132","article-title":"Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors","volume":"47","author":"Harnett","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.ijcard.2006.05.071_bib25","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0272-6386(96)90357-1","article-title":"Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention","volume":"27","author":"Levin","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ijcard.2006.05.071_bib26","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJM199005313222203","article-title":"Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study","volume":"322","author":"Levy","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2006.05.071_bib27","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/ndt\/15.9.1425","article-title":"Effects of hemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure","volume":"15","author":"McMahon","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ijcard.2006.05.071_bib28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11886-003-0050-z","article-title":"The prognostic significance of renal dysfunction in patients with chronic systolic heart failure","volume":"5","author":"Laskar","year":"2003","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.ijcard.2006.05.071_bib29","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1046\/j.1523-1755.2000.07512.x","article-title":"Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia","volume":"75","author":"Fine","year":"2000","journal-title":"Kidney Inter Suppl"},{"key":"10.1016\/j.ijcard.2006.05.071_bib30","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/j.1523-1755.1998.00830.x","article-title":"Mesangiolytic glomerulopathy in severe congestive heart failure","volume":"53","author":"Yoshida","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.ijcard.2006.05.071_bib31","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2141.1992.tb08200.x","article-title":"Cellular sites of extrarenal and renal erythropoietin production in anemic rats","volume":"81","author":"Schuster","year":"1992","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijcard.2006.05.071_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/ajkd.2001.25174","article-title":"Erythropoietin and transferrin metabolism in nephrotic syndrome","volume":"38","author":"Vaziri","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ijcard.2006.05.071_bib33","doi-asserted-by":"crossref","first-page":"R166","DOI":"10.1152\/ajpregu.2002.282.1.R166","article-title":"Decreased hematopoiesis in bone marrow of mice with congestive heart failure","volume":"282","author":"Iversen","year":"2002","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.ijcard.2006.05.071_bib34","first-page":"7","article-title":"Advances in the anemia of chronic disease","volume":"70","author":"Means","year":"1999","journal-title":"Int J Hematol"},{"key":"10.1016\/j.ijcard.2006.05.071_bib35","first-page":"47","article-title":"Hepcidin\u2014the iron regulatory hormone","volume":"26","author":"Rossi","year":"2005","journal-title":"Clin Biochem Rev"},{"key":"10.1016\/j.ijcard.2006.05.071_bib36","first-page":"S2819","article-title":"Anemia in chronic heart failure: the relationship to inflammatory cytokine production and prognostic importance","volume":"106","author":"Bolger","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2006.05.071_bib37","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1161\/01.CIR.0000052623.16194.80","article-title":"Hemodilution is common in patients with advanced heart failure","volume":"107","author":"Androne","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2006.05.071_bib38","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1093\/eurheartj\/ehi389","article-title":"The importance of the gastrointestinal system in the pathogenesis of heart failure","volume":"26","author":"Krack","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2006.05.071_bib39","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1093\/ndt\/14.8.1836","article-title":"The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin","volume":"14","author":"Macdougall","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ijcard.2006.05.071_bib40","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1172\/JCI10557","article-title":"Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting enzyme-deficient mice","volume":"106","author":"Cole","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijcard.2006.05.071_bib41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1046\/j.1523-1755.2001.00773.x","article-title":"Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway","volume":"60","author":"Gossmann","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.ijcard.2006.05.071_bib42","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s004240051012","article-title":"Dose-dependent effect of angiotensin II on human erythropoietin production","volume":"439","author":"Freudenthaler","year":"2000","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.ijcard.2006.05.071_bib43","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1507\/endocrj1954.31.741","article-title":"Effect of angiotensin II on secretion of adrenal androgens","volume":"31","author":"Yanase","year":"1984","journal-title":"Endocrinol Jpn"},{"key":"10.1016\/j.ijcard.2006.05.071_bib44","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/00007890-199810270-00015","article-title":"Erythrocytosis after renal transplantation represents an abnormality of insulin-like growth factor-I and its binding proteins","volume":"66","author":"Brox","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.ijcard.2006.05.071_bib45","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1172\/JCI118484","article-title":"Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline","volume":"97","author":"Azizi","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijcard.2006.05.071_bib46","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2174\/1568026043451311","article-title":"Hct-lowering effect following inactivation of renin\u2013angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers","volume":"4","author":"Marathias","year":"2004","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.ijcard.2006.05.071_bib47","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jacc.2004.10.038","article-title":"Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction","volume":"45","author":"Ishani","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2006.05.071_bib48","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/00007890-200108150-00035","article-title":"Comparison of the effects of enalapril and losartan on posttransplantation erythrocytosis in renal transplant recipients: prospective randomized study","volume":"72","author":"Yildiz","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.ijcard.2006.05.071_bib49","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S0140-6736(02)07812-1","article-title":"Angiotensin-converting-enzyme inhibition therapy in altitude polycythemia: a prospective randomized trial","volume":"359","author":"Plata","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2006.05.071_bib50","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/S0735-1097(00)00613-6","article-title":"The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations","volume":"35","author":"Silverberg","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2006.05.071_bib51","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/S0735-1097(01)01248-7","article-title":"The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study","volume":"37","author":"Silverberg","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2006.05.071_bib52","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/ndt\/18.1.141","article-title":"The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron","volume":"18","author":"Silverberg","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ijcard.2006.05.071_bib53","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1161\/01.CIR.0000044914.42696.6A","article-title":"Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure","volume":"107","author":"Mancini","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2006.05.071_bib54","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000081621","article-title":"Effects of treatment with epoetin Beta on outcomes in patients with anaemia and chronic heart failure","volume":"28","author":"Silverberg","year":"2005","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.ijcard.2006.05.071_bib55","first-page":"670","article-title":"Prevalence, prognostic importance and therapeutic implications of anemia in heart failure","volume":"57","author":"Mishra","year":"2005","journal-title":"Indian Heart J"},{"key":"10.1016\/j.ijcard.2006.05.071_bib56","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0301-472X(03)00006-7","article-title":"Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin","volume":"31","author":"Egrie","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1016\/j.ijcard.2006.05.071_bib57","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/01.fjc.0000167013.77092.c4","article-title":"Once-monthly administration of darbepoetin alfa for the treatment of patients with chronic heart failure and anemia: a pharmacokinetic and pharmacodynamic investigation","volume":"46","author":"Cleland","year":"2005","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ijcard.2006.05.071_bib58","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ejheart.2005.07.001","article-title":"Clinical trials update from the European Society of Cardiology Heart Failure meeting and the American College of Cardiology: darbepoetin alfa study, ECHOS, and ASCOT-BPLA","volume":"7","author":"Cleland","year":"2005","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ijcard.2006.05.071_bib59","first-page":"61A","article-title":"Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimen of darbepoetin alfa on hemoglobin response and symptoms in patients with heart failure and anemia","volume":"47","author":"van Veldhuisen","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.ijcard.2006.05.071_bib60","first-page":"S182","article-title":"Clinical practice guidelines for anemia of chronic kidney disease: update 2000","volume":"37","author":"NKF-K\/DOQI","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ijcard.2006.05.071_bib61","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low Hct values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2006.05.071_bib62","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1186\/cc2405","article-title":"Age of blood: does it make a difference?","author":"Offner","year":"2004","journal-title":"Crit Care"},{"key":"10.1016\/j.ijcard.2006.05.071_bib63","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood.V84.6.1703.1703","article-title":"Biologic effects of leukocytes present in transfused cellular blood products","volume":"84","author":"Bordin","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.ijcard.2006.05.071_bib64","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/BF00315364","article-title":"Hemodynamic oxygen transport and 2,3-diphosphoglycerate changes after transfusion of patients in acute respiratory failure","volume":"12","author":"Kahn","year":"1986","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijcard.2006.05.071_bib65","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1172\/JCI18200","article-title":"A novel protective effect of erythropoietin in the infarcted heart","volume":"112","author":"Parsa","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijcard.2006.05.071_bib66","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/nm723","article-title":"HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration","volume":"8","author":"Grimm","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.ijcard.2006.05.071_bib67","doi-asserted-by":"crossref","first-page":"330A","DOI":"10.1016\/S0735-1097(03)81998-8","article-title":"A functional erythropoietin receptor in a rat heart is linked to anti-apoptotic effects","volume":"41","author":"van der Meer","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2006.05.071_bib68","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1073\/pnas.051606598","article-title":"Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress","volume":"98","author":"Siren","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijcard.2006.05.071_bib69","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1073\/pnas.91.9.3974","article-title":"Erythropoietin receptor mRNA expression in human endothelial cells","volume":"91","author":"Anagnostou","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijcard.2006.05.071_bib70","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jacc.2005.01.043","article-title":"High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention","volume":"45","author":"Namiuchi","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2006.05.071_bib71","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/BF03402029","article-title":"Erythropoietin therapy for acute stroke is both safe and beneficial","volume":"8","author":"Ehrenreich","year":"2002","journal-title":"Mol Med"},{"key":"10.1016\/j.ijcard.2006.05.071_bib72","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1182\/blood-2003-01-0223","article-title":"Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization","volume":"102","author":"Heeschen","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ijcard.2006.05.071_bib73","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1006\/mvre.2002.2426","article-title":"Erythropoietin and VEGF exhibit equal angiogenic potential","volume":"64","author":"Jaquet","year":"2002","journal-title":"Microvasc Res"},{"key":"10.1016\/j.ijcard.2006.05.071_bib74","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jacc.2005.03.044","article-title":"Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction","volume":"46","author":"van der Meer","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2006.05.071_bib75","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/j.lfs.2005.09.053","article-title":"Mechanism of the cardioprotection of rhEPO pretreatment on suppressing the inflammatory response in ischemia\u2013reperfusion","volume":"78","author":"Liu","year":"2006","journal-title":"Life Sci"},{"key":"10.1016\/j.ijcard.2006.05.071_bib76","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/glia.20289","article-title":"Epo protects SOD2-deficient mouse astrocytes from damage by oxidative stress","volume":"53","author":"Liu","year":"2006","journal-title":"Glia"},{"key":"10.1016\/j.ijcard.2006.05.071_bib77","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1182\/blood.V82.7.2010.2010","article-title":"Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen","volume":"82","author":"Beguin","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.ijcard.2006.05.071_bib78","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1634\/theoncologist.8-1-99","article-title":"Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients","volume":"8","author":"Littlewood","year":"2003","journal-title":"Oncologist"},{"issue":"Suppl 7","key":"10.1016\/j.ijcard.2006.05.071_bib79","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/ndt\/16.suppl_7.25","article-title":"Hyporesponsiveness to recombinant human erythropoietin","volume":"16","author":"Drueke","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ijcard.2006.05.071_bib80","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/clpt.1992.10","article-title":"A pharmacodynamic model of erythropoietin therapy for uremic anemia","volume":"51","author":"Uehlinger","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijcard.2006.05.071_bib81","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood.V84.4.1056.1056","article-title":"Prediction of response to erythropoietin treatment in chronic anemia of cancer","volume":"84","author":"Ludwig","year":"1994","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.ijcard.2006.05.071_bib82","first-page":"S38","article-title":"Prediction of response to treatment with recombinant human erythropoietin in anaemia associated with cancer","volume":"15","author":"Beguin","year":"1998","journal-title":"Med Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.ijcard.2006.05.071_bib83","first-page":"S19","article-title":"Pre-treatment erythropoietin levels cannot be used to predict individual response to epoetin alfa in anaemic cancer patients","volume":"21","author":"LibraPharm","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ijcard.2006.05.071_bib84","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/ndt\/13.5.1206","article-title":"High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients","volume":"13","author":"Albitar","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ijcard.2006.05.071_bib85","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1093\/ndt\/14.8.1912","article-title":"The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hyper-trophy in haemodialysis patients","volume":"14","author":"Erturk","year":"1999","journal-title":"Nephrol Dial Transplant"},{"issue":"suppl 4","key":"10.1016\/j.ijcard.2006.05.071_bib86","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1093\/ndt\/15.suppl_4.43","article-title":"European best practice guidelines 14\u201316: inadequate response to epoetin","volume":"15","author":"Horl","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ijcard.2006.05.071_bib87","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1046\/j.1523-1755.2001.00028.x","article-title":"Effects of angiotensin-converting enzyme inhibitors on the treatment of anemia with erythropoietin","volume":"60","author":"Hayashi","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.ijcard.2006.05.071_bib88","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/ndt\/14.8.2047","article-title":"The effect of angiotensin II receptor antagonist on the exogenous erythropoietin requirement of haemodialysis patients","volume":"14","author":"Chew","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ijcard.2006.05.071_bib89","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000045257","article-title":"Angiotensin-converting enzyme inhibitors but not angiotensin II AT 1 receptor antagonists affect erythropoiesis in patients with anemia of end-stage renal disease","volume":"81","author":"Schiffl","year":"1999","journal-title":"Nephron"},{"key":"10.1016\/j.ijcard.2006.05.071_bib90","first-page":"91","article-title":"ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance","volume":"19","author":"Saudan","year":"2006","journal-title":"J Nephrol"},{"key":"10.1016\/j.ijcard.2006.05.071_bib91","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1182\/blood.V89.3.1052","article-title":"Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency","volume":"89","author":"Punnonen","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.ijcard.2006.05.071_bib92","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1086\/382878","article-title":"Iron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy","volume":"38","author":"Teehan","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijcard.2006.05.071_bib93","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3201\/eid0503.990305","article-title":"Iron loading and disease surveillance","volume":"5","author":"Weinberg","year":"1999","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijcard.2006.05.071_bib94","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/ndt\/17.6.962","article-title":"High dose intravenous iron: a note of caution","volume":"17","author":"Kletzmayr","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ijcard.2006.05.071_bib95","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMra041809","article-title":"Anemia of chronic disease","volume":"352","author":"Weiss","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2006.05.071_bib96","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1159\/000188905","article-title":"Intravenous ferric saccharate as an iron supplement in dialysis patients","volume":"72","author":"Silverberg","year":"1996","journal-title":"Nephron"},{"key":"10.1016\/j.ijcard.2006.05.071_bib97","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.2004.08.119","article-title":"Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial","volume":"22","author":"Auerbach","year":"2004","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527306006917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527306006917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T21:27:22Z","timestamp":1587158842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527306006917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":97,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S0167527306006917"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2006.05.071","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}